← Back to Search

Anti-mitotic Agent

Nanosomal Docetaxel for Triple Negative Breast Cancer

Phase 3
Recruiting
Research Sponsored by Jina Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to two.
Must not have
Patients who are unwilling or unable to follow protocol requirements.
Uncontrolled diabetes or infection.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years after study initiation
Awards & highlights
Pivotal Trial
No Placebo-Only Group
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

This trial tests a new, safer form of the cancer drug docetaxel, called Nanosomal Docetaxel Lipid Suspension (NDLS), in patients with advanced or spreading triple-negative breast cancer. NDLS aims to reduce side effects by using tiny fat particles. The drug works by stopping cancer cells from dividing and growing. Docetaxel is a widely used chemotherapy drug, and newer formulations like Nanosomal Docetaxel Lipid Suspension (NDLS) aim to improve its efficacy and reduce toxicity.

Who is the study for?
This trial is for patients with triple-negative breast cancer who have had one prior chemotherapy regimen and are not currently pregnant or breastfeeding. They must have a measurable lesion, an ECOG status of 0-2, normal heart function, and adequate organ function. Exclusions include hypersensitivity to Docetaxel, HER2 positive or hormone receptor-positive cancers, uncontrolled diabetes/infection, recent participation in another drug study, known brain metastases (unless asymptomatic), significant neuropathy or cardiac issues.
What is being tested?
The trial tests Nanosomal Docetaxel Lipid Suspension at two doses (75 mg/m2 and 100 mg/m2) against the standard Taxotere® at 100 mg/m2 in patients with advanced breast cancer. It aims to improve safety by eliminating certain excipients found in conventional formulations. The efficacy will be measured using RECIST guidelines across three groups of participants.
What are the potential side effects?
Potential side effects may include those commonly associated with chemotherapy such as fatigue, nausea, hair loss, low blood cell counts leading to increased infection risk and bleeding problems; nerve damage causing pain or numbness; allergic reactions; and potential heart complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast cancer is advanced and previous chemotherapy didn't work.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
My breast cancer is confirmed to be triple negative.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am willing and able to follow the study's requirements.
Select...
I do not have uncontrolled diabetes or infections.
Select...
I do not have recent or severe heart problems.
Select...
I do not have severe nerve damage from previous treatments.
Select...
My cancer is positive for HER2 and either estrogen or progesterone receptors.
Select...
I have received Docetaxel for my cancer after it spread.
Select...
I am diagnosed with HIV.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years after study initiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years after study initiation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of the patients with Objective Response Rate (i.e., CR + PR) as the Best Overall Response Rate (i.e., CR + PR) in the test arm (NDLS) compared to reference arm (Taxotere)
Secondary study objectives
Incidence of adverse events as assessed by clinical examination, and/or laboratory parameters
Progression free survival (PFS)
To evaluate the overall survival (OS) of the patients

Side effects data

From 2014 Phase 4 trial • 32 Patients • NCT01301729
59%
Leukopenia
56%
Neutropenia
34%
Hypoaesthesia
31%
Agranulocytosis
22%
Alopecia
22%
Asthenia
19%
Pyrexia
16%
Nail disorder
16%
Oedema peripheral
16%
Diarrhoea
16%
Hypophagia
13%
Alanine aminotransferase increased
13%
Neurotoxicity
13%
Cough
13%
Vomting
9%
Musculoskeletal pain
9%
Headache
9%
Aspartate aminotransferase increased
9%
Chest discomfort
9%
Rash
9%
Pigmentation disorder
9%
Nausea
9%
Bone marrow failure
9%
Anaemia
6%
Transaminases increased
6%
Insomnia
6%
Constipation
6%
Mouth ulceration
6%
Nasopharyngitis
6%
Paronychia
6%
Flushing
6%
Face oedema
6%
Thrombocytopenia
3%
Infection
3%
Upper respiratory tract infection
3%
Completed suicide
3%
Cataract
100%
80%
60%
40%
20%
0%
Study treatment Arm
Trastuzumab

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)Experimental Treatment1 Intervention
Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
Group II: Nanosomal Docetaxel Lipid Suspension - 75 mg/m2Experimental Treatment1 Intervention
Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
Group III: R, Taxotere® (100 mg/m2)Active Control1 Intervention
Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for breast cancer, such as docetaxel, work by inhibiting cell division, which is essential for cancer cell growth. Docetaxel stabilizes microtubules, preventing their disassembly and leading to cell death. The Nanosomal Docetaxel Lipid Suspension (NDLS) improves upon this by using a lipid-based delivery system to eliminate harmful excipients, reduce side effects, and potentially enhance drug delivery to the tumor. This approach aims to provide more effective treatment with fewer adverse effects, improving outcomes and quality of life for breast cancer patients.
Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer.Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

Find a Location

Who is running the clinical trial?

Jina Pharmaceuticals Inc.Lead Sponsor
3 Previous Clinical Trials
627 Total Patients Enrolled
Intas Pharmaceuticals, Ltd.Industry Sponsor
3 Previous Clinical Trials
468 Total Patients Enrolled
Lambda Therapeutic Research Ltd.Industry Sponsor
7 Previous Clinical Trials
1,228 Total Patients Enrolled
Dr. Ravi AlamchandaniStudy ChairLambda Therapeutic Research Ltd.

Media Library

Nanosomal Docetaxel Lipid Suspension (Anti-mitotic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT03671044 — Phase 3
Breast Cancer Research Study Groups: R, Taxotere® (100 mg/m2), Nanosomal Docetaxel Lipid Suspension - 75 mg/m2, T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
Breast Cancer Clinical Trial 2023: Nanosomal Docetaxel Lipid Suspension Highlights & Side Effects. Trial Name: NCT03671044 — Phase 3
Nanosomal Docetaxel Lipid Suspension (Anti-mitotic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03671044 — Phase 3
~89 spots leftby Dec 2025